XML 31 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1

Revenues (Tables)

9 Months Ended

Sep. 30, 2017

Segment Reporting [Abstract]

Summary of net revenue

The Company’s net revenues consisted of the following for the three and nine months ended September 30, 2017 and 2016:

	Three months ended September 30,								Nine months ended September 30,
	2017				2016				2017				2016
Products:
Acetadote	$	1,342,457			$	1,807,495			$	4,331,675			$	5,532,893
Omeclamox-Pak	190,835				752,808				1,213,635				2,154,596
Kristalose	2,749,966				3,671,397				8,037,994				10,915,276
Vaprisol	385,541				496,279				1,346,793				1,286,126
Caldolor	896,640				1,357,289				2,762,790				3,060,441
Ethyol	2,566,611				519,400				8,325,254				519,400
Totect	2,916,425				—				2,916,425				—
Other	148,486				187,085				566,277				475,388
Total net revenues	$	11,196,961			$	8,791,753			$	29,500,843			$	23,944,120

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration